Source: Annual Congress 2013 –Biomarkers in asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Molnar, B. Süto, B. Biri, L. Nagy, S. Keki, I. Ruzsics (Pécs, Debrecen, Hungary). Methylated arginine derivatives can differ stable and unstable patients with COPD. Eur Respir J 2013; 42: Suppl. 57, 394

Member's Comments

No comment yet.

Related content which might interest you: What is the best biomarker of COPD stability? Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015 Role of inflammatory biomarkers in COPD Source: International Congress 2016 – Systemic biomarkers Year: 2016 Midrange-proadrenomedullin in stable state predicts severe exacerbation of COPD Source: International Congress 2016 – Exploring mechanisms in health and disease Year: 2016 Are there any differences between Tunisian and European COPD phenotypes? Source: International Congress 2016 – Best abstracts in COPD management Year: 2016 Clinical and inflammatory characteristics of 'unreported' COPD exacerbations Source: Annual Congress 2013 –COPD mechanisms Year: 2013 BNP level in patients with COPD exacerbations Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 COPD: Influence of patients’ nutritive status on the exacerbations rate Source: International Congress 2016 – COPD diagnosis and management Year: 2016 CAT in COPD phenotypes (POPE study) Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 COPD on anti-GERD therapy remains at higher risk for severe exacerbation Source: International Congress 2014 – COPD exacerbations Year: 2014 Outcomes in patients with COPD during a 3 year follow-up Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 Heterogeneity inside group D COPD patients: About 827 cases Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Symptom profile of exacerbations in earlier and later COPD Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes Year: 2013 Evaluation of the GOLD 2011 severity criteria across the COPD spectrum Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 The serum level of surfactantproteind in patients with chronic obstructive pulmonary disease, depending on the nutrtional status Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015 Eosinophilia as marker of outcome in hospitalised patients with AECOPD Source: Annual Congress 2013 –COPD and infections Year: 2013 GOLD and phenotypes: The new Czech COPD guidelines Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Characterization of readmissions in patients hospitalized with COPD exacerbation Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Gender differences in hospitalized patients with acute exacerbation of COPD Source: Annual Congress 2013 –COPD biomarkers Year: 2013 The relation of comorbidities with the exacerbation severity in patients with COPD Source: Annual Congress 2013 –COPD mechanisms Year: 2013 The prognostic value of cardiac and inflammatory biomarkers in acute exacerbations of COPD Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016